A fundamental goal in cancer research is to understand the mechanisms of cell
transformation. This is key to develo** more efficient cancer detection methods and …

Protein post-translational modification (PTM) is a regulatory mechanism for protein activity
modulation, localization, expression, and interactions with other cellular molecules. It …

Colorectal cancer is caused by a sequence of somatic genomic alterations affecting driver
genes in core cancer pathways. Here, to understand the functional and prognostic impact of …

FBXW7 is an E3 ubiquitin ligase that targets proteins for proteasome-mediated degradation
and is mutated in various cancer types. Here, we use CRISPR base editors to introduce …

Despite the existence of good catalogues of cancer genes,, identifying the specific mutations
of those genes that drive tumorigenesis across tumour types is still a largely unsolved …

Only around 20% of the human proteome is considered to be druggable with small-molecule
antagonists. This leaves some of the most compelling therapeutic targets outside the reach …

Mutations in genes that confer a selective advantage to hematopoietic stem cells (HSCs)
drive clonal hematopoiesis (CH). While some CH drivers have been identified, the …

Highlights•Actionable alterations should be prioritized by using validated rankings for
treatment tailoring.•High-throughput genomics could refine drivers and find new targets, mini …

The ubiquitin-proteasome system (UPS) is the primary route for selective protein
degradation in human cells. The UPS is an attractive target for novel cancer therapies, but …

Protein-targeted degradation is an emerging and promising therapeutic approach. The
specificity of degradation and the maintenance of cellular homeostasis are determined by …